- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Neutropenia occurs when patients have a low level of neutrophils which is a type of white blood cells.
According to our latest study, the global Neutropenia Biologic Drug Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Neutropenia Biologic Drug Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neutropenia Biologic Drug Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neutropenia Biologic Drug Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neutropenia Biologic Drug Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neutropenia Biologic Drug Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neutropenia Biologic Drug Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neutropenia Biologic Drug Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Novartis, Pfizer, Baxter International and Cellerant Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neutropenia Biologic Drug Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Filgrastim
Pegfilgrastim
Lenograstim
Lipegfilgrastim
Sargramostim
Market segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Market segment by players, this report covers
Amgen
Novartis
Pfizer
Baxter International
Cellerant Therapeutics
Dong-A ST Co.,Ltd.
Myelo Therapeutics GmbH
Sanofi
Teva Pharmaceutical Industries Ltd.
Kyowa Kirin
CVS Health
Partner Therapeutics
Enzychem Lifesciences Corporation
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neutropenia Biologic Drug Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neutropenia Biologic Drug Treatment, with revenue, gross margin and global market share of Neutropenia Biologic Drug Treatment from 2018 to 2023.
Chapter 3, the Neutropenia Biologic Drug Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neutropenia Biologic Drug Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neutropenia Biologic Drug Treatment.
Chapter 13, to describe Neutropenia Biologic Drug Treatment research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Neutropenia Biologic Drug Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neutropenia Biologic Drug Treatment by Type
1.3.1 Overview: Global Neutropenia Biologic Drug Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type in 2022
1.3.3 Filgrastim
1.3.4 Pegfilgrastim
1.3.5 Lenograstim
1.3.6 Lipegfilgrastim
1.3.7 Sargramostim
1.4 Global Neutropenia Biologic Drug Treatment Market by Application
1.4.1 Overview: Global Neutropenia Biologic Drug Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Retail Pharmacies
1.4.3 Hospital Pharmacies
1.4.4 Online Pharmacies
1.5 Global Neutropenia Biologic Drug Treatment Market Size & Forecast
1.6 Global Neutropenia Biologic Drug Treatment Market Size and Forecast by Region
1.6.1 Global Neutropenia Biologic Drug Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Neutropenia Biologic Drug Treatment Market Size by Region, (2018-2029)
1.6.3 North America Neutropenia Biologic Drug Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Neutropenia Biologic Drug Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Neutropenia Biologic Drug Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Neutropenia Biologic Drug Treatment Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Neutropenia Biologic Drug Treatment Product and Solutions
2.1.4 Amgen Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Neutropenia Biologic Drug Treatment Product and Solutions
2.2.4 Novartis Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Neutropenia Biologic Drug Treatment Product and Solutions
2.3.4 Pfizer Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Baxter International
2.4.1 Baxter International Details
2.4.2 Baxter International Major Business
2.4.3 Baxter International Neutropenia Biologic Drug Treatment Product and Solutions
2.4.4 Baxter International Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Baxter International Recent Developments and Future Plans
2.5 Cellerant Therapeutics
2.5.1 Cellerant Therapeutics Details
2.5.2 Cellerant Therapeutics Major Business
2.5.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product and Solutions
2.5.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Cellerant Therapeutics Recent Developments and Future Plans
2.6 Dong-A ST Co.,Ltd.
2.6.1 Dong-A ST Co.,Ltd. Details
2.6.2 Dong-A ST Co.,Ltd. Major Business
2.6.3 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product and Solutions
2.6.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Dong-A ST Co.,Ltd. Recent Developments and Future Plans
2.7 Myelo Therapeutics GmbH
2.7.1 Myelo Therapeutics GmbH Details
2.7.2 Myelo Therapeutics GmbH Major Business
2.7.3 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product and Solutions
2.7.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Myelo Therapeutics GmbH Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Neutropenia Biologic Drug Treatment Product and Solutions
2.8.4 Sanofi Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries Ltd.
2.9.1 Teva Pharmaceutical Industries Ltd. Details
2.9.2 Teva Pharmaceutical Industries Ltd. Major Business
2.9.3 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product and Solutions
2.9.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.10 Kyowa Kirin
2.10.1 Kyowa Kirin Details
2.10.2 Kyowa Kirin Major Business
2.10.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Product and Solutions
2.10.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Kyowa Kirin Recent Developments and Future Plans
2.11 CVS Health
2.11.1 CVS Health Details
2.11.2 CVS Health Major Business
2.11.3 CVS Health Neutropenia Biologic Drug Treatment Product and Solutions
2.11.4 CVS Health Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 CVS Health Recent Developments and Future Plans
2.12 Partner Therapeutics
2.12.1 Partner Therapeutics Details
2.12.2 Partner Therapeutics Major Business
2.12.3 Partner Therapeutics Neutropenia Biologic Drug Treatment Product and Solutions
2.12.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Partner Therapeutics Recent Developments and Future Plans
2.13 Enzychem Lifesciences Corporation
2.13.1 Enzychem Lifesciences Corporation Details
2.13.2 Enzychem Lifesciences Corporation Major Business
2.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product and Solutions
2.13.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Enzychem Lifesciences Corporation Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neutropenia Biologic Drug Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Neutropenia Biologic Drug Treatment by Company Revenue
3.2.2 Top 3 Neutropenia Biologic Drug Treatment Players Market Share in 2022
3.2.3 Top 6 Neutropenia Biologic Drug Treatment Players Market Share in 2022
3.3 Neutropenia Biologic Drug Treatment Market: Overall Company Footprint Analysis
3.3.1 Neutropenia Biologic Drug Treatment Market: Region Footprint
3.3.2 Neutropenia Biologic Drug Treatment Market: Company Product Type Footprint
3.3.3 Neutropenia Biologic Drug Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Neutropenia Biologic Drug Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Neutropenia Biologic Drug Treatment Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Neutropenia Biologic Drug Treatment Market Forecast by Application (2024-2029)
6 North America
6.1 North America Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2029)
6.2 North America Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2029)
6.3 North America Neutropenia Biologic Drug Treatment Market Size by Country
6.3.1 North America Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2029)
7.2 Europe Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2029)
7.3 Europe Neutropenia Biologic Drug Treatment Market Size by Country
7.3.1 Europe Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
7.3.3 France Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region
8.3.1 Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Region (2018-2029)
8.3.2 China Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8.3.5 India Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
9 South America
9.1 South America Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2029)
9.2 South America Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2029)
9.3 South America Neutropenia Biologic Drug Treatment Market Size by Country
9.3.1 South America Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country
10.3.1 Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Neutropenia Biologic Drug Treatment Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Neutropenia Biologic Drug Treatment Market Drivers
11.2 Neutropenia Biologic Drug Treatment Market Restraints
11.3 Neutropenia Biologic Drug Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Neutropenia Biologic Drug Treatment Industry Chain
12.2 Neutropenia Biologic Drug Treatment Upstream Analysis
12.3 Neutropenia Biologic Drug Treatment Midstream Analysis
12.4 Neutropenia Biologic Drug Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Neutropenia Biologic Drug Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Neutropenia Biologic Drug Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Neutropenia Biologic Drug Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Neutropenia Biologic Drug Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Amgen Company Information, Head Office, and Major Competitors
Table 6. Amgen Major Business
Table 7. Amgen Neutropenia Biologic Drug Treatment Product and Solutions
Table 8. Amgen Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Amgen Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Neutropenia Biologic Drug Treatment Product and Solutions
Table 13. Novartis Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Pfizer Company Information, Head Office, and Major Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Neutropenia Biologic Drug Treatment Product and Solutions
Table 18. Pfizer Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Pfizer Recent Developments and Future Plans
Table 20. Baxter International Company Information, Head Office, and Major Competitors
Table 21. Baxter International Major Business
Table 22. Baxter International Neutropenia Biologic Drug Treatment Product and Solutions
Table 23. Baxter International Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Baxter International Recent Developments and Future Plans
Table 25. Cellerant Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Cellerant Therapeutics Major Business
Table 27. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product and Solutions
Table 28. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Cellerant Therapeutics Recent Developments and Future Plans
Table 30. Dong-A ST Co.,Ltd. Company Information, Head Office, and Major Competitors
Table 31. Dong-A ST Co.,Ltd. Major Business
Table 32. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product and Solutions
Table 33. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Dong-A ST Co.,Ltd. Recent Developments and Future Plans
Table 35. Myelo Therapeutics GmbH Company Information, Head Office, and Major Competitors
Table 36. Myelo Therapeutics GmbH Major Business
Table 37. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product and Solutions
Table 38. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Myelo Therapeutics GmbH Recent Developments and Future Plans
Table 40. Sanofi Company Information, Head Office, and Major Competitors
Table 41. Sanofi Major Business
Table 42. Sanofi Neutropenia Biologic Drug Treatment Product and Solutions
Table 43. Sanofi Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Sanofi Recent Developments and Future Plans
Table 45. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 46. Teva Pharmaceutical Industries Ltd. Major Business
Table 47. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product and Solutions
Table 48. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 50. Kyowa Kirin Company Information, Head Office, and Major Competitors
Table 51. Kyowa Kirin Major Business
Table 52. Kyowa Kirin Neutropenia Biologic Drug Treatment Product and Solutions
Table 53. Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Kyowa Kirin Recent Developments and Future Plans
Table 55. CVS Health Company Information, Head Office, and Major Competitors
Table 56. CVS Health Major Business
Table 57. CVS Health Neutropenia Biologic Drug Treatment Product and Solutions
Table 58. CVS Health Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. CVS Health Recent Developments and Future Plans
Table 60. Partner Therapeutics Company Information, Head Office, and Major Competitors
Table 61. Partner Therapeutics Major Business
Table 62. Partner Therapeutics Neutropenia Biologic Drug Treatment Product and Solutions
Table 63. Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Partner Therapeutics Recent Developments and Future Plans
Table 65. Enzychem Lifesciences Corporation Company Information, Head Office, and Major Competitors
Table 66. Enzychem Lifesciences Corporation Major Business
Table 67. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product and Solutions
Table 68. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Enzychem Lifesciences Corporation Recent Developments and Future Plans
Table 70. Global Neutropenia Biologic Drug Treatment Revenue (USD Million) by Players (2018-2023)
Table 71. Global Neutropenia Biologic Drug Treatment Revenue Share by Players (2018-2023)
Table 72. Breakdown of Neutropenia Biologic Drug Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 73. Market Position of Players in Neutropenia Biologic Drug Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 74. Head Office of Key Neutropenia Biologic Drug Treatment Players
Table 75. Neutropenia Biologic Drug Treatment Market: Company Product Type Footprint
Table 76. Neutropenia Biologic Drug Treatment Market: Company Product Application Footprint
Table 77. Neutropenia Biologic Drug Treatment New Market Entrants and Barriers to Market Entry
Table 78. Neutropenia Biologic Drug Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 79. Global Neutropenia Biologic Drug Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 80. Global Neutropenia Biologic Drug Treatment Consumption Value Share by Type (2018-2023)
Table 81. Global Neutropenia Biologic Drug Treatment Consumption Value Forecast by Type (2024-2029)
Table 82. Global Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023)
Table 83. Global Neutropenia Biologic Drug Treatment Consumption Value Forecast by Application (2024-2029)
Table 84. North America Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 85. North America Neutropenia Biologic Drug Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 86. North America Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 87. North America Neutropenia Biologic Drug Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 88. North America Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 89. North America Neutropenia Biologic Drug Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 90. Europe Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Europe Neutropenia Biologic Drug Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Europe Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 93. Europe Neutropenia Biologic Drug Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 94. Europe Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Neutropenia Biologic Drug Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 97. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 98. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 99. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 100. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 101. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 102. South America Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 103. South America Neutropenia Biologic Drug Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 104. South America Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 105. South America Neutropenia Biologic Drug Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 106. South America Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 107. South America Neutropenia Biologic Drug Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 109. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 110. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 111. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 112. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 113. Middle East & Africa Neutropenia Biologic Drug Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 114. Neutropenia Biologic Drug Treatment Raw Material
Table 115. Key Suppliers of Neutropenia Biologic Drug Treatment Raw Materials
List of Figures
Figure 1. Neutropenia Biologic Drug Treatment Picture
Figure 2. Global Neutropenia Biologic Drug Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type in 2022
Figure 4. Filgrastim
Figure 5. Pegfilgrastim
Figure 6. Lenograstim
Figure 7. Lipegfilgrastim
Figure 8. Sargramostim
Figure 9. Global Neutropenia Biologic Drug Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application in 2022
Figure 11. Retail Pharmacies Picture
Figure 12. Hospital Pharmacies Picture
Figure 13. Online Pharmacies Picture
Figure 14. Global Neutropenia Biologic Drug Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Neutropenia Biologic Drug Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Neutropenia Biologic Drug Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Neutropenia Biologic Drug Treatment Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Neutropenia Biologic Drug Treatment Consumption Value Market Share by Region in 2022
Figure 19. North America Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Neutropenia Biologic Drug Treatment Revenue Share by Players in 2022
Figure 25. Neutropenia Biologic Drug Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Neutropenia Biologic Drug Treatment Market Share in 2022
Figure 27. Global Top 6 Players Neutropenia Biologic Drug Treatment Market Share in 2022
Figure 28. Global Neutropenia Biologic Drug Treatment Consumption Value Share by Type (2018-2023)
Figure 29. Global Neutropenia Biologic Drug Treatment Market Share Forecast by Type (2024-2029)
Figure 30. Global Neutropenia Biologic Drug Treatment Consumption Value Share by Application (2018-2023)
Figure 31. Global Neutropenia Biologic Drug Treatment Market Share Forecast by Application (2024-2029)
Figure 32. North America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Neutropenia Biologic Drug Treatment Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. France Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Neutropenia Biologic Drug Treatment Consumption Value Market Share by Region (2018-2029)
Figure 49. China Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. India Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Neutropenia Biologic Drug Treatment Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Neutropenia Biologic Drug Treatment Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Neutropenia Biologic Drug Treatment Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Neutropenia Biologic Drug Treatment Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Neutropenia Biologic Drug Treatment Consumption Value (2018-2029) & (USD Million)
Figure 66. Neutropenia Biologic Drug Treatment Market Drivers
Figure 67. Neutropenia Biologic Drug Treatment Market Restraints
Figure 68. Neutropenia Biologic Drug Treatment Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Neutropenia Biologic Drug Treatment in 2022
Figure 71. Manufacturing Process Analysis of Neutropenia Biologic Drug Treatment
Figure 72. Neutropenia Biologic Drug Treatment Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
